The estimated Net Worth of Katherine A. Eade is at least $477 mil dollars as of 9 August 2019. Ms. Eade owns over 39,915 units of Harvard Bioscience stock worth over $343,887 and over the last 7 years she sold HBIO stock worth over $0. In addition, she makes $132,956 as Independent Director at Harvard Bioscience.
Katherine has made over 1 trades of the Harvard Bioscience stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 39,915 units of HBIO stock worth $98,989 on 9 August 2019.
The largest trade she's ever made was buying 39,915 units of Harvard Bioscience stock on 9 August 2019 worth over $98,989. On average, Katherine trades about 2,348 units every 0 days since 2017. As of 9 August 2019 she still owns at least 121,515 units of Harvard Bioscience stock.
You can see the complete history of Ms. Eade stock trades at the bottom of the page.
Katherine Anne Eade J.D. serves as Independent Director of the Company. Ms. Eade is Vice President, Strategic Commercial Affairs at Align Technology, a position she has held since 2019, and prior to that was Deputy General Counsel of La-Z-Boy Incorporated from 2018 to 2019. Ms. Eade has more than 18 years of experience advising public companies on M&A and other significant corporate transactions, governance matters and capital markets. Prior to joining La-Z-Boy, Ms. Eade was the Director, M&A Law and Transactions for Corning Incorporated and Division Counsel for Corning’s Life Sciences and Pharmaceutical Technologies divisions. Her life science acquisitions for Corning included the $730 million purchase of BD’s Discovery Labware business. Previous to her work at Corning, Ms. Eade was an attorney at Cleary Gottlieb Steen & Hamilton LLP, a leading international law firm, for over seven years. Earlier in her career, she served as a law clerk for Judge Morton I. Greenberg of the U.S. Court of Appeals for the Third Circuit. Ms. Eade earned a J.D., cum laude, from Harvard Law School and a B.A. in Government, summa cum laude, from Cornell University.
As the Independent Director of Harvard Bioscience, the total compensation of Katherine Eade at Harvard Bioscience is $132,956. There are 9 executives at Harvard Bioscience getting paid more, with James Green having the highest compensation of $2,422,600.
Katherine Eade is 46, she's been the Independent Director of Harvard Bioscience since 2017. There are 10 older and no younger executives at Harvard Bioscience. The oldest executive at Harvard Bioscience Inc. is John Kennedy, 71, who is the Independent Director.
Katherine's mailing address filed with the SEC is 84 October Hill Rd, Holliston, MA 01746, USA.
Over the last 21 years, insiders at Harvard Bioscience have traded over $10,145,146 worth of Harvard Bioscience stock and bought 754,658 units worth $2,380,232 . The most active insiders traders include Earl R Lewis, Bertrand Loy y David Green. On average, Harvard Bioscience executives and independent directors trade stock every 43 days with the average trade being worth of $182,054. The most recent stock trade was executed by James W Green on 13 June 2024, trading 10,000 units of HBIO stock currently worth $29,100.
harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Harvard Bioscience executives and other stock owners filed with the SEC include: